Skip to main content
S&P 5007,353.73-4.36%DOW51,523.06-3.44%NASDAQ24,315.00-5.52%BTC$75,720.00-5.51%ETH$2,228.43-7.73%GOLD$4,097.70+0.61%OIL$91.07+3.35%
Smart Investors Daily
SID Premium
AS

NASDAQ · ASBPW

Aspire Biopharma Holdings, Inc.

Healthcare · Biotechnology

$0.02

Up+$0.00 (+33.85%)

Updated Nov 5, 2026, 9:55 PM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
6.21M
P/E ratio
-9.59
Dividend yield
0.00%
52-week range
$0.01 – $0.03
Volume
174
Avg. volume
36.09K

Price performance · ASBPW

ASBPW price history

1M range · 5 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

ASBPW closed at $0.02 after 5 trading sessions, up 31.82% for the selected period.

Last close
$0.02
Period change
+31.82%
Period low
$0.01
Period high
$0.02
Daily close
View OHLC price history
ASBPW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$0.0174$0.0174$0.0174$0.0174174
Oct 30, 2026$0.0131$0.0131$0.013$0.01335.11K
Oct 28, 2026$0.0131$0.0131$0.0131$0.01311.46K
Oct 23, 2026$0.0153$0.0153$0.0153$0.01536K
Oct 13, 2026$0.0131$0.0132$0.0131$0.0132200

Latest ASBPW news

The latest Smart Investors Daily articles mentioning ASBPW.

Stock researchCompany · Overview

ASBPW research

Overview

Company profile and research snapshot.

Company profile

Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program

Brings total authorized repurchase to $10 millionReflects leadership's view that Aspire-Lakewood's share price does not reflect the Company's financial strength or long-term growth opportunityIncreased authorization supported by strength of newly acquired Dura Control Systems Corp's (DCSC) full year 2025 and six months ended June 30, 2026 revenue of approximately $209.5 million and Adjusted EBITDA1 of $22.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By